Citations

Clear

626 citation(s) found for "Mehta, SH".

Is preoperative ciliary body and iris anatomical configuration a predictor of malignant glaucoma development?
Prata, Tiago S. , Dorairaj, Syril , Moraes, Carlos GV De, Mehta, Siddhart, Sbeity, Zaher, Tello, Celso , Liebmann, Jeffrey M. , Ritch, Robert , Dorairaj, Syril

Mayo Clinic

Clinical & Experimental Ophthalmology | December 25, 2012 | Volume: 41 | Issue: 6 | Pages: 541-545

10.1111/ceo.12057 | PMID 23279576 Get It

AbstractBackgroundTo investigate anatomical configuration of ciliary body and iris using ultrasound biomicroscopy as a predictor of malignant glaucoma development.DesignRetrospective study in a tertiary care hospital.ParticipantsCohort of 31 consecutive patients diagnosed with post‐surgical malignant glaucoma.MethodsAnterior chamber angle, iris and ciliary body configuration of involved eyes that had ultrasound biomicroscopy evaluation prior to the malignant glaucoma onset were evaluated. In cases with no presurgical ultrasound biomicroscopy exam of the involved eye, images from the fellow eye (imaged within 6 months) were analysed.Main Outcome MeasuresQualitative parameters.ResultsThirty‐one eyes (31 patients) had confirmed malignant glaucoma between 1996 and 2008. Most patients were women (65%) and had an anatomical narrow angle or angle‐closure glaucoma (77%). Mean intraocular pressure at diagnosis was 30.4 ± 13.5 mmHg. The most common operation was trabeculectomy with mitomycin C (55%, 17/31 eyes), combined (3/17) or not (14/17) with cataract extraction and intraocular lens implantation. Among these 31 cases, we were able to evaluate the ultrasound biomicroscopy images of 13 patients (13 eyes) including involved eyes imaged prior to the malignant glaucoma onset or eligible fellow eyes. A narrow angle with or without iridotrabecular contact was found in all eyes. A large and/or anteriorly positioned ciliary body associated with an iris root angulating forward and centrally, revealing a plateau iris configuration, was noticed in 85% (11/13) of these eyes.ConclusionIdentification of plateau iris configuration by ultrasound biomicroscopy should be considered as a possible predictor of post‐operative malignant glaucoma development.
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Cairncross, Gregory, Wang, Meihua , Shaw, Edward , Jenkins, Robert B. , Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Laperrière, Normand , Curran, Walter, Mehta, Minesh P. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | October 16, 2012 | Volume: 31 | Issue: 3 | Pages: 337-343

10.1200/jco.2012.43.2674 | PMID 23071247 Get It

Purpose Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown. Patients and Methods Eligible patients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone. The primary end point was overall survival (OS). Results Two hundred ninety-one eligible patients were randomly assigned: 148 to PCV plus RT and 143 to RT. For the entire cohort, there was no difference in median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79; 95% CI, 0.60 to 1.04; P = .1). Patients with codeleted tumors lived longer than those with noncodeleted tumors (PCV plus RT: 14.7 v 2.6 years, HR = 0.36, 95% CI, 0.23 to 0.57, P < .001; RT: 7.3 v 2.7 years, HR = 0.40, 95% CI, 0.27 to 0.60, P < .001), and the median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v 7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P = .03). For those with noncodeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR = 0.85; 95% CI, 0.58 to 1.23; P = .39). In Cox models that included codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01). Conclusion For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
Shaw, Edward G. , Wang, Meihua , Coons, Stephen W., Brachman, David, Buckner, Jan C. , Stelzer, K. , Barger, Geoffrey, Brown, Paul D. , Mehta, Minesh P. , Gilbert, Mark R. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | July 31, 2012 | Volume: 30 | Issue: 25 | Pages: 3065-3070

10.1200/jco.2011.35.8598 | PMID 22851558 Get It

Purpose A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG). Patients and Methods Eligibility criteria included supratentorial WHO grade 2 LGG, age 18 to 39 years with subtotal resection/biopsy, or age ≥ 40 years with any extent resection. Patients were randomly assigned to RT alone or RT followed by six cycles of PCV. Survival was compared by using the modified Wilcoxon and log-rank tests. Results In all, 251 patients were accrued from 1998 to 2002. Median overall survival (OS) time and 5-year OS rates for RT versus RT + PCV were 7.5 years versus not reached and 63% versus 72%, respectively (hazard ratio [HR]; 0.72; 95% CI, 0.47 to 1.10; P = .33; log-rank P = .13). Median progression-free survival (PFS) time and 5-year PFS rates for RT versus RT + PCV were 4.4 years versus not reached and 46% versus 63%, respectively (HR, 0.6; 95% CI, 0.41 to 0.86; P = .06; log-rank P = .005). OS and PFS were similar for all patients between years 0 and 2. After 2 years, OS and PFS curves separated significantly, favoring RT + PCV. For 2-year survivors (n = 211), the probability of OS for an additional 5 years was 74% with RT + PCV versus 59% with RT alone (HR, 0.52; 95% CI, 0.30 to 0.90; log-rank P = .02). Conclusion PFS but not OS was improved for adult patients with LGG receiving RT + PCV versus RT alone. On post hoc analysis, for 2-year survivors, the addition of PCV to RT conferred a survival advantage, suggesting a delayed benefit for chemotherapy.
Cerecyte Coil Trial
Molyneux, Andrew , Clarke, Alison, Sneade, Mary , Mehta, Ziyah, Coley, Stuart C., Kallmes, David F. , Fox, Allan J. , Roy, Daniel C.

Mayo Clinic

Stroke | July 27, 2012 | Volume: 43 | Issue: 10 | Pages: 2544-2550

10.1161/strokeaha.112.657254 | PMID 22836352 Get It

Background and Purpose— We report the primary outcome of the Cerecyte Coil Trial, a randomized trial to determine whether polymer-loaded Cerecyte coils compared with Micrus bare platinum coils improved the proportion of patients with angiographic occlusion of the aneurysm at 6 months when assessed by a core laboratory. The secondary objectives were to compare the clinical outcomes and retreatment rates in the 2 groups. Methods— Five hundred patients between 18 and 70 years of age with a ruptured or unruptured target aneurysm were randomized to be treated with either Cerecyte or bare platinum coils in 23 centers worldwide. Two hundred forty-nine patients were assigned to Cerecyte coils and 251 to bare platinum coils. Analysis was by intention to treat. Results— Four hundred ninety-four patients were eligible for analysis. Four hundred eighty-one patients underwent coil treatment of their aneurysm, 227 patients with recently ruptured aneurysms and 254 with unruptured aneurysms. Four hundred thirty-three follow-up angiograms were assessed by the core laboratory; 127 of 215 (59%) and 118 of 218 (54%) in the Cerecyte and bare platinum groups, respectively, fulfilled the trial prespecified definition of success, namely that the treated aneurysm showed complete angiographic occlusion, had stable neck remnant, or improved in angiographic appearance compared with the end-of-treatment angiogram ( P =0.17). Late retreatment was performed in 25 of 452 (5.5%) patients, 17 (7.7%) Cerecyte versus 8 (3.5%) bare platinum ( P =0.064; range, 4–34 months). The clinical outcomes did not differ between the groups. Conclusion— There was no significant difference at 6 months in the angiographic outcomes between Cerecyte coils and bare platinum coils when assessed by the core laboratory. Clinical Trial Registration Information— URL: www.controlled-trials.com . Unique Identifier: ISRCTN82461286.
Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review
Caine, Chip, Mehta, Minesh P. , Gondi, Vinai , Laack, Nadia N. , Mehta, Minesh P

Mayo Clinic

Expert Review of Anticancer Therapy | May 17, 2012 | Volume: 12 | Issue: 5 | Pages: 655-667

10.1586/era.12.34 | PMID 22594900 Get It

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Dimopoulos, Meletios Α. , Kyle, Robert A. , Fermand, Jean-Paul, Rajkumar, S. Vincent , Miguel, Jesús F. San , Chanan‐Khan, Asher , Joshua, Douglas, Mehta, Jayesh, Avet‐Loiseau, Hervé , Beksaç, Meral , Moreau, Philippe , Goldschmidt, Hartmut , Boccadoro, Mario , Kumar, Shaji , Munshi, Nikhil C. , 3, on behalf of the International Myeloma Workshop Consensus Panel, Ludwig, Heinz , Gertz, Morie A. , Anderson, Kenneth C. , Singhal, Seema , Giralt, Sergio , Jagannath, Sundar , 3, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Beksac, Meral

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4701-4705

10.1182/blood-2010-10-299529 | PMID 21292778 Get It

AbstractA panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
Verwey, Nicolaas A. , Flier, Wiesje M. van der , Blennow, Kaj , Clark, Christopher M. , Sokolow, Sophie , Hartmann, Tobias , Kapaki, E. , Lannfelt, Lars , Parnetti, Lucilla , Petzold, Axel , Pirttilä, Tuula, Saleh, Lanja , Skinningsrud, Anders, Swieten, John C. van , Wiltfang, Jens , Younkin, Steve, Scheltens, Philip , Blankenstein, Marinus A. , Deyn, Peter Paul De , Galasko, Douglas , Hampel, Harald , Mehta, Pankaj D , Verbeek, Marcel M. , Parnetti, Lucilla , van der Flier, Wiesje M , Scheltens, Philip , Wiltfang, Jens , Van Swieten, John C

Mayo Clinic

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine | April 23, 2009 | Volume: 46 | Issue: 3 | Pages: 235-240

10.1258/acb.2009.008232 | PMID 19342441 Get It

Background Different cerebrospinal fluid (CSF) amyloid-beta 1–42 (A β 1–42 ), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres. Methods Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured A β 1–42 , Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex. Results In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for A β 1–42 , Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest ® ( N = 13) for A β 1–42 , lower interCV were calculated (22%). The centres that participated in both years ( N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008. Conclusions The highest variability was found for A β 1–42 . The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Inwards, David J. , Spies, Stewart, Wiseman, Gregory A., Patton, David R. , Erwin, William D. , Rademaker, Alfred , Weitner, Bing Bing, Williams, Stephanie , Tallman, Martin S. , Micallef, Ivana N. , Mehta, Jayesh, Evens, Andrew M. , Zimmer, Michael, Molina, Arturo , Gordon, Leo I. , Winter, Jane N. , Singhal, Seema , White, Christine A. , Gordon, Leo I , Evens, Andrew M , Patton, David R

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 10 | Pages: 1653-1659

10.1200/jco.2008.19.2245 | PMID 19255322 Get It

Purpose To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 (90Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation. Patients and Methods Eligible patients had relapsed or refractory CD20+ non-Hodgkin's lymphoma (NHL). Individualized 90Y activities were based on dosimetry and were calculated to deliver cohort-defined RAD (1 to 17 Gy) to critical organs with three to six patients per cohort. The therapeutic dose of 90Y ibritumomab tiuxetan was followed by high-dose BEAM and autologous transplantation. Results Forty-four patients were treated. Thirty percent of patients had achieved less than a partial remission to their most recent therapy and would not have been eligible for autologous transplantation at most centers. The toxicity profile was similar to that associated with high-dose BEAM chemotherapy. Two dose-limiting toxicities occurred at the 17 Gy dose level, which made 15 Gy the recommended maximum-tolerated RAD. Although eight patients received at least twice the conventional dose of 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have resulted in a wide range of RAD; nearly 25% of patient cases would have received 17 Gy or more, and many would have received less than 10 Gy. With a median follow-up of 33 months for all patients, the estimated 3-year progression-free and overall survivals were 43% and 60%, respectively. Conclusion Dose-escalated 90Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy. Careful dosimetry is required to avoid toxicity and undertreatment.